Sharma S. Prabhakar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sharma S. Prabhakar has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Arunita Chatterjee
Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
4 shared publications Jacqueline Tumarin
Department of Internal Medicine, Texas Tech University Health Sciences Centre, United States
2 shared publications- Anne M. Deschamps
Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC 29403, USA
1 shared publication Betty Lonis
Departments of *Internal Medicine, †Physiology, and ‡Pathology, Texas Tech University Health Sciences Center, Lubbock, Texas
1 shared publication- Charis Eng
Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, USA
1 shared publication - Fahmida Shaik
Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
1 shared publication
Latest Publications
- Open Access
Non-Proteinuric Diabetic Kidney Disease: A Comprehensive Review
Diabetic kidney disease (DKD) persists as the leading cause of chronic kidney disease (CKD) and often leads to end-stage renal disease (ESRD). Worldwide, 30–50% of patients with diabetes are affected by DKD, while DKD contributes to about half of ESRD. Previously, DKD had been defined based on overt proteinuria—that is, a urine albumin-to-creatinine ratio (UACR) above 300 mg/g—after a stage of microalbuminuria (UACR 30–300 mg/g). However, emerging data suggest that a significant number of patients develop renal functional decline without albuminuria, suggesting that DKD can occur in the absence of protein excretion. This phenotype of normoalbuminuric or non-proteinuric DKD (NA-DKD or NP-DKD) is emerging as an important clinical entity. It is characterized by a gradual decline in renal function, commonly with an annual reduction in estimated glomerular filtration rate (eGFR) > 3 mL/min/1.73 m2 or an eGFR < 60 mL/min/1.73 m2, while the UACR remains < 30 mg/g. Growing rates of NP-DKD expose limitations inherent in traditional models of DKD pathogenesis and underscore the need for diagnostic and therapeutic paradigms that are not reliant on albuminuria-only criteria. Here, we present a comprehensive review of the NP-DKD to guide a more inclusive model of DKD pathogenesis, its diagnosis, and therapy.
Open AccessNon-Proteinuric Diabetic Kidney Disease: A Comprehensive Review
Diabetic kidney disease (DKD) persists as the leading cause of chronic kidney disease (CKD) and often leads to end-stage renal disease (ESRD). Worldwide, 30–50% of patients with diabetes are affected by DKD, while DKD contributes to about half of ESRD. Previously, DKD had been defined based on overt proteinuria—that is, a urine albumin-to-creatinine ratio (UACR) above 300 mg/g—after a stage of microalbuminuria (UACR 30–300 mg/g). However, emerging data suggest that a significant number of patients develop renal functional decline without albuminuria, suggesting that DKD can occur in the absence of protein excretion. This phenotype of normoalbuminuric or non-proteinuric DKD (NA-DKD or NP-DKD) is emerging as an important clinical entity. It is characterized by a gradual decline in renal function, commonly with an annual reduction in estimated glomerular filtration rate (eGFR) > 3 mL/min/1.73 m2 or an eGFR < 60 mL/min/1.73 m2, while the UACR remains < 30 mg/g. Growing rates of NP-DKD expose limitations inherent in traditional models of DKD pathogenesis and underscore the need for diagnostic and therapeutic paradigms that are not reliant on albuminuria-only criteria. Here, we present a comprehensive review of the NP-DKD to guide a more inclusive model of DKD pathogenesis, its diagnosis, and therapy.
- Open Access
An Overview of Sex-Based Differences in the Onset and Progression of DKD in the Well-Known Model, ZSF1 Rats
A better understanding of diabetic kidney disease (DKD) will help optimize its management. Few animal models replicate human DKD characteristics as closely as ZSF1 male rats. To address the male-specific focus in murine model systems, we aimed to characterize the manifestation of DKD in ZSF1 females and compare them with ZSF1 males and control rats (CD). ZSF1 males become obese at an early age. ZSF1 females are fatter and heavier than CD females but remain smaller, lighter, and more active than ZSF1 males throughout their lives. Male, but not female, ZSF1 rats become hypertensive with age. ZSF1 females have a higher heart rate in early life, which reduces significantly with age. ZSF1 males exhibit significant hyperglycemia from an early age. In contrast, female ZSF1 are not overly hyperglycemic; however, their blood glucose levels trend higher than those of CD females, and the difference is statistically significant. Both ZSF1 males and females develop progressive proteinuria. ZSF1 females, therefore, display various features of DKD: higher-trending blood glucose levels, hyperlipidemia, and progressive proteinuria, but not hypertension. Thus, ZSF1 female rats may be a suitable model for studying DKD without hypertension and for testing the effects of DKD-relevant drug responses in females.
Open AccessAn Overview of Sex-Based Differences in the Onset and Progression of DKD in the Well-Known Model, ZSF1 Rats
A better understanding of diabetic kidney disease (DKD) will help optimize its management. Few animal models replicate human DKD characteristics as closely as ZSF1 male rats. To address the male-specific focus in murine model systems, we aimed to characterize the manifestation of DKD in ZSF1 females and compare them with ZSF1 males and control rats (CD). ZSF1 males become obese at an early age. ZSF1 females are fatter and heavier than CD females but remain smaller, lighter, and more active than ZSF1 males throughout their lives. Male, but not female, ZSF1 rats become hypertensive with age. ZSF1 females have a higher heart rate in early life, which reduces significantly with age. ZSF1 males exhibit significant hyperglycemia from an early age. In contrast, female ZSF1 are not overly hyperglycemic; however, their blood glucose levels trend higher than those of CD females, and the difference is statistically significant. Both ZSF1 males and females develop progressive proteinuria. ZSF1 females, therefore, display various features of DKD: higher-trending blood glucose levels, hyperlipidemia, and progressive proteinuria, but not hypertension. Thus, ZSF1 female rats may be a suitable model for studying DKD without hypertension and for testing the effects of DKD-relevant drug responses in females.
- Open Access
- 7 January 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1499473
Cellular cross-talk drives mesenchymal transdifferentiation in diabetic kidney disease
While changes in glomerular function and structure may herald diabetic kidney disease (DKD), many studies have underscored the significance of tubule-interstitial changes in the progression of DKD. Indeed, tubule-interstitial fibrosis may be the most important determinant of progression of DKD as in many forms of chronic glomerulopathies. The mechanisms underlying the effects of tubular changes on glomerular function in DKD have intrigued many investigators, and therefore, the signaling mechanisms underlying the cross-talk between tubular cells and glomerular cells have been the focus of investigation in many recent studies. Additionally, the observations of slowing of glomerular filtration rate (GFR) decline and reduction of proteinuria by recent drugs such as SGLT-2 blockers, whose primary mechanism of action is on proximal tubules, further strengthen the concept of cross-talk between the tubular and glomerular cells. Recently, the focus of research on the pathogenesis of DKD has primarily centered around exploring the cross-talk between various signaling pathways in the diabetic kidney as well as cross-talk between tubular and glomerular endothelial cells and podocytes with special relevance to epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndoMT). The focus of this review is to provide a general description of cell-to-cell cross-talk in the diabetic kidney and to highlight these concepts with evidence in relation to the physiology and pathophysiology of DKD.
- 7 January 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1499473
Open AccessCellular cross-talk drives mesenchymal transdifferentiation in diabetic kidney disease
While changes in glomerular function and structure may herald diabetic kidney disease (DKD), many studies have underscored the significance of tubule-interstitial changes in the progression of DKD. Indeed, tubule-interstitial fibrosis may be the most important determinant of progression of DKD as in many forms of chronic glomerulopathies. The mechanisms underlying the effects of tubular changes on glomerular function in DKD have intrigued many investigators, and therefore, the signaling mechanisms underlying the cross-talk between tubular cells and glomerular cells have been the focus of investigation in many recent studies. Additionally, the observations of slowing of glomerular filtration rate (GFR) decline and reduction of proteinuria by recent drugs such as SGLT-2 blockers, whose primary mechanism of action is on proximal tubules, further strengthen the concept of cross-talk between the tubular and glomerular cells. Recently, the focus of research on the pathogenesis of DKD has primarily centered around exploring the cross-talk between various signaling pathways in the diabetic kidney as well as cross-talk between tubular and glomerular endothelial cells and podocytes with special relevance to epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndoMT). The focus of this review is to provide a general description of cell-to-cell cross-talk in the diabetic kidney and to highlight these concepts with evidence in relation to the physiology and pathophysiology of DKD.
- Open Access
- 11 July 2024
- Published by OAE Publishing Inc. in Vessel Plus
- Vol. 8
Role of inflammation in the progression of diabetic kidney disease
Diabetic kidney disease (DKD) is a global health burden and the leading cause of end-stage renal disease. Its clinical management focuses on controlling hyperglycemia, hypertension, and hyperlipidemia. While the progression of DKD can be slowed with intervention, it cannot be stopped or reversed yet. The pathogenesis of DKD is complex, with an interplay of numerous signaling pathways, and research continues to decipher the players and their role, be it beneficial or pathogenic. Inflammation is an essential defense of our bodies against internal or external insults. The injuries that trigger inflammation range from pathogenic infections and wounds to dysregulated metabolism. Inflammation is helpful only if it is controlled and subsides after it has helped defend the individual against the insult. Uncontrolled or chronic inflammation is recognized as a contributor to numerous chronic diseases. Dysregulated inflammation plays a role in multiple aspects of DKD: glomerular hyperfiltration, mesangial expansion, podocyte injury, tubular injury, basement membrane thickening, fibrosis, and scarring. Since inflammation plays an integral role in the progression of DKD, targeting it for therapy is also reasonable. There is a growing trend of targeting inflammation as a therapeutic approach, with new targets being discovered and evaluated drugs every year. The exponential increase in literature necessitates a comprehensive summary of current information, hence this review.
- 11 July 2024
- Published by OAE Publishing Inc. in Vessel Plus
- Vol. 8
Open AccessRole of inflammation in the progression of diabetic kidney disease
Diabetic kidney disease (DKD) is a global health burden and the leading cause of end-stage renal disease. Its clinical management focuses on controlling hyperglycemia, hypertension, and hyperlipidemia. While the progression of DKD can be slowed with intervention, it cannot be stopped or reversed yet. The pathogenesis of DKD is complex, with an interplay of numerous signaling pathways, and research continues to decipher the players and their role, be it beneficial or pathogenic. Inflammation is an essential defense of our bodies against internal or external insults. The injuries that trigger inflammation range from pathogenic infections and wounds to dysregulated metabolism. Inflammation is helpful only if it is controlled and subsides after it has helped defend the individual against the insult. Uncontrolled or chronic inflammation is recognized as a contributor to numerous chronic diseases. Dysregulated inflammation plays a role in multiple aspects of DKD: glomerular hyperfiltration, mesangial expansion, podocyte injury, tubular injury, basement membrane thickening, fibrosis, and scarring. Since inflammation plays an integral role in the progression of DKD, targeting it for therapy is also reasonable. There is a growing trend of targeting inflammation as a therapeutic approach, with new targets being discovered and evaluated drugs every year. The exponential increase in literature necessitates a comprehensive summary of current information, hence this review.
- 1 March 2013
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 61 (3) , 551-557
Inhibition of Renin-Angiotensin System: Implications for Diabetes Control and Prevention
Several large-scale clinical studies have consistently demonstrated that use of inhibitors of renin-angiotensin system such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers was associated with significant reduction of new-onset diabetes in patients with insulin resistance such as primary hypertension. Such observations stimulated major investigations into the interaction of angiotensin and insulin signaling systems, which in turn led to the discovery of a cross talk at several steps between the 2 pathways. Evidence from these clinical trials and from the experimental models of insulin resistance including our findings in ZSF rat and other animal models will be discussed in this review.
- 1 March 2013
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 61 (3) , 551-557
Inhibition of Renin-Angiotensin System: Implications for Diabetes Control and Prevention
Several large-scale clinical studies have consistently demonstrated that use of inhibitors of renin-angiotensin system such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers was associated with significant reduction of new-onset diabetes in patients with insulin resistance such as primary hypertension. Such observations stimulated major investigations into the interaction of angiotensin and insulin signaling systems, which in turn led to the discovery of a cross talk at several steps between the 2 pathways. Evidence from these clinical trials and from the experimental models of insulin resistance including our findings in ZSF rat and other animal models will be discussed in this review.
- 1 December 2012
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 60 (8) , 1141-1146
Translational Research Challenges: Finding the Right Animal Models
Translation of scientific discoveries into meaningful human applications, particularly novel therapies of human diseases, requires development of suitable animal models. Experimental approaches to test new drugs in preclinical phases often necessitated animal models that not only replicate human disease in etiopathogenesis and pathobiology but also biomarkers development and toxicity prediction. Whereas the transgenic and knockout techniques have revolutionized manipulation of rodents and other species to get greater insights into human disease pathogenesis, we are far from generating ideal animal models of most human disease states. The challenges in using the currently available animal models for translational research, particularly for developing potentially new drugs for human disease, coupled with the difficulties in toxicity prediction have led some researchers to develop a scoring system for translatability. These aspects and the challenges in selecting an animal model among those that are available to study human disease pathobiology and drug development are the topics covered in this detailed review.
- 1 December 2012
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 60 (8) , 1141-1146
Translational Research Challenges: Finding the Right Animal Models
Translation of scientific discoveries into meaningful human applications, particularly novel therapies of human diseases, requires development of suitable animal models. Experimental approaches to test new drugs in preclinical phases often necessitated animal models that not only replicate human disease in etiopathogenesis and pathobiology but also biomarkers development and toxicity prediction. Whereas the transgenic and knockout techniques have revolutionized manipulation of rodents and other species to get greater insights into human disease pathogenesis, we are far from generating ideal animal models of most human disease states. The challenges in using the currently available animal models for translational research, particularly for developing potentially new drugs for human disease, coupled with the difficulties in toxicity prediction have led some researchers to develop a scoring system for translatability. These aspects and the challenges in selecting an animal model among those that are available to study human disease pathobiology and drug development are the topics covered in this detailed review.
- Open Access
- 13 April 2012
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 10 (1) , 72
Engaging basic scientists in translational research: identifying opportunities, overcoming obstacles
This report is based on the Federation of American Societies for Experimental Biology’s symposium, “Engaging basic Scientists in Translational Research: Identifying Opportunities, Overcoming Obstacles,” held in Chevy Chase, MD, March 24–25, 2011. Meeting participants examined the benefits of engaging basic scientists in translational research, the challenges to their participation in translational research, and the roles that research institutions, funding organizations, professional societies, and scientific publishers can play to address these challenges.
- 13 April 2012
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 10 (1) , 72
Open AccessEngaging basic scientists in translational research: identifying opportunities, overcoming obstacles
This report is based on the Federation of American Societies for Experimental Biology’s symposium, “Engaging basic Scientists in Translational Research: Identifying Opportunities, Overcoming Obstacles,” held in Chevy Chase, MD, March 24–25, 2011. Meeting participants examined the benefits of engaging basic scientists in translational research, the challenges to their participation in translational research, and the roles that research institutions, funding organizations, professional societies, and scientific publishers can play to address these challenges.
- Open Access
- 1 November 2007
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 18 (11) , 2945-2952
Diabetic Nephropathy Is Associated with Oxidative Stress and Decreased Renal Nitric Oxide Production
The pathogenesis of diabetic nephropathy remains far from clear, partly due to the lack of a suitable animal model that mimics human renal disease in type 2 diabetes. In this study, the natural history of renal manifestations in ZSF1 rats, a recently developed rodent model of type 2 diabetes, is described. Male ZSF1 rats developed obesity and hyperglycemia by 20 weeks of age on a high-carbohydrate diet. They also developed systolic and diastolic hypertension, hypercholesterolemia, profound hypertriglyceridemia, proteinuria, and renal failure. Renal histology demonstrated changes consistent with early diabetic nephropathy, including arteriolar thickening, tubular dilation and atrophy, glomerular basement membrane thickening, and mesangial expansion. Furthermore, renal nitric oxide production was decreased, and homogenates from renal cortices demonstrated reduced expression of renal endothelial and inducible nitric oxide synthases. These changes were associated with increased urinary levels and renal expression of 8-hydroxydeoxyguanosine, an indicator of mitochondrial oxidative stress, as well as with increased renal peroxynitrite formation. Administration of either insulin or the antioxidant alpha-lipoic acid decreased proteinuria and oxidative stress, but only the former slowed progression of renal failure. We conclude that ZSF1 rats represent the best available rat model to study nephropathy from type 2 diabetes and that the renal lesions are associated with increased oxidative stress and decreased renal nitric oxide availability.
- 1 November 2007
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 18 (11) , 2945-2952
Open AccessDiabetic Nephropathy Is Associated with Oxidative Stress and Decreased Renal Nitric Oxide Production
The pathogenesis of diabetic nephropathy remains far from clear, partly due to the lack of a suitable animal model that mimics human renal disease in type 2 diabetes. In this study, the natural history of renal manifestations in ZSF1 rats, a recently developed rodent model of type 2 diabetes, is described. Male ZSF1 rats developed obesity and hyperglycemia by 20 weeks of age on a high-carbohydrate diet. They also developed systolic and diastolic hypertension, hypercholesterolemia, profound hypertriglyceridemia, proteinuria, and renal failure. Renal histology demonstrated changes consistent with early diabetic nephropathy, including arteriolar thickening, tubular dilation and atrophy, glomerular basement membrane thickening, and mesangial expansion. Furthermore, renal nitric oxide production was decreased, and homogenates from renal cortices demonstrated reduced expression of renal endothelial and inducible nitric oxide synthases. These changes were associated with increased urinary levels and renal expression of 8-hydroxydeoxyguanosine, an indicator of mitochondrial oxidative stress, as well as with increased renal peroxynitrite formation. Administration of either insulin or the antioxidant alpha-lipoic acid decreased proteinuria and oxidative stress, but only the former slowed progression of renal failure. We conclude that ZSF1 rats represent the best available rat model to study nephropathy from type 2 diabetes and that the renal lesions are associated with increased oxidative stress and decreased renal nitric oxide availability.
- 1 November 2006
- Published by Springer Nature in Current Diabetes Reports
- Vol. 6 (6) , 455-462
Lipids and diabetic nephropathy
Although several factors may mediate the development and progression of diabetic nephropathy, hyperlipidemia is now considered an independent and major determinant of progression of renal disease in diabetes. The following discussion focuses on the experimental evidence that incriminates hyperlipidemia as a pathogenic factor for diabetic nephropathy and the potential mechanisms that may mediate renal injury from hyperlipidemia, as well as the clinical studies involving therapeutic interventions for hyperlipidemia and their impact on progression of diabetic renal disease.
- 1 November 2006
- Published by Springer Nature in Current Diabetes Reports
- Vol. 6 (6) , 455-462
Lipids and diabetic nephropathy
Although several factors may mediate the development and progression of diabetic nephropathy, hyperlipidemia is now considered an independent and major determinant of progression of renal disease in diabetes. The following discussion focuses on the experimental evidence that incriminates hyperlipidemia as a pathogenic factor for diabetic nephropathy and the potential mechanisms that may mediate renal injury from hyperlipidemia, as well as the clinical studies involving therapeutic interventions for hyperlipidemia and their impact on progression of diabetic renal disease.